<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9822537</article-id>
    <article-id pub-id-type="pmid">36576005</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btac831</article-id>
    <article-id pub-id-type="publisher-id">btac831</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Revana: a comprehensive tool for regulatory variant analysis and visualization of cancer genomes</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2489-7265</contrib-id>
        <name>
          <surname>Ulrich</surname>
          <given-names>Elias</given-names>
        </name>
        <aff><institution>Division of Pediatric Neurooncology, Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
        <aff><institution>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
        <xref rid="btac831-cor1" ref-type="corresp"/>
        <!--elias.ulrich@kitz-heidelberg.de-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pfister</surname>
          <given-names>Stefan M</given-names>
        </name>
        <aff><institution>Division of Pediatric Neurooncology, Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
        <aff><institution>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
        <aff><institution>Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jäger</surname>
          <given-names>Natalie</given-names>
        </name>
        <aff><institution>Division of Pediatric Neurooncology, Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
        <aff><institution>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)</institution>, Heidelberg 69120, <country country="DE">Germany</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Alkan</surname>
          <given-names>Can</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btac831-cor1">To whom correspondence should be addressed. <email>elias.ulrich@kitz-heidelberg.de</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2022-12-28">
      <day>28</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>28</day>
      <month>12</month>
      <year>2022</year>
    </pub-date>
    <volume>39</volume>
    <issue>1</issue>
    <elocation-id>btac831</elocation-id>
    <history>
      <date date-type="received">
        <day>01</day>
        <month>7</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>19</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="editorial-decision">
        <day>22</day>
        <month>12</month>
        <year>2022</year>
      </date>
      <date date-type="corrected-typeset">
        <day>03</day>
        <month>1</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btac831.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>As non-coding driver mutations move more into the focus of cancer research, a comprehensive and easy-to-use software solution for regulatory variant analysis and data visualization is highly relevant. The interpretation of regulatory variants in large tumor genome cohorts requires specialized analysis and visualization of multiple layers of data, including for example breakpoints of structural variants, enhancer elements and additional available gene locus annotation, in the context of changes in gene expression.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We introduce a user-friendly tool, Revana (REgulatory Variant ANAlysis), that can aggregate and visually represent regulatory variants from cancer genomes in a gene-centric manner. It requires whole-genome and RNA sequencing data of a cohort of tumor samples and creates interactive HTML reports summarizing the most important regulatory events.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p>Revana is implemented in R and JavaScript. It is available for download as an R package under &lt;<ext-link xlink:href="https://github.com/KiTZ-Heidelberg/revana" ext-link-type="uri">https://github.com/KiTZ-Heidelberg/revana</ext-link>&gt;. Sample results can be viewed under &lt;<ext-link xlink:href="https://github.com/KiTZ-Heidelberg/revana-demo-report" ext-link-type="uri">https://github.com/KiTZ-Heidelberg/revana-demo-report</ext-link>&gt; and a short walkthrough is available under &lt;<ext-link xlink:href="https://github.com/KiTZ-Heidelberg/revana-demo-data" ext-link-type="uri">https://github.com/KiTZ-Heidelberg/revana-demo-data</ext-link>&gt;.</p>
      </sec>
      <sec id="s5">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>The sensitive and specific detection of driver mutations is an important task in cancer genomics. While variants in the protein-coding space are nowadays mostly relatively easy to detect, the reliable detection of non-coding driver variants is more challenging yet equally relevant (<xref rid="btac831-B13" ref-type="bibr">Rheinbay <italic toggle="yes">et al.</italic>, 2020</xref>). Non-coding drivers involve diverse mechanisms and usually function by altering the expression of certain, often spatially proximal genes. They do not alter the amino-acid structure of the translated proteins and are thus called regulatory variants. Prominent examples are recurrent single-nucleotide variants (SNVs) in the promoter of <italic toggle="yes">TERT</italic> (<xref rid="btac831-B5" ref-type="bibr">Horn <italic toggle="yes">et al.</italic>, 2013</xref>; <xref rid="btac831-B6" ref-type="bibr">Huang <italic toggle="yes">et al.</italic>, 2013</xref>), that upregulate the gene and thus maintain telomeres across many cancer entities (<xref rid="btac831-B12" ref-type="bibr">Remke, 2013</xref>; <xref rid="btac831-B15" ref-type="bibr">Vinagre <italic toggle="yes">et al.</italic>, 2013</xref>).</p>
    <p>Another mechanism is enhancer hijacking, where structural variants (SVs) alter the surrounding 3D DNA structure of genes and juxtapose them to highly active regulatory regions like gene enhancers. By upregulating <italic toggle="yes">GFI1/GFI1B</italic> and <italic toggle="yes">PRDM</italic>, enhancer hijacking drives pediatric medulloblastoma (<xref rid="btac831-B10" ref-type="bibr">Northcott <italic toggle="yes">et al.</italic>, 2014</xref>, <xref rid="btac831-B9" ref-type="bibr">2017</xref>) among many other tumor entities (<xref rid="btac831-B3" ref-type="bibr">Haller <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btac831-B4" ref-type="bibr">Helmsauer <italic toggle="yes">et al.</italic>, 2020</xref>; <xref rid="btac831-B8" ref-type="bibr">Montefiori <italic toggle="yes">et al.</italic>, 2021</xref>).</p>
    <p>Previously developed methods to discover regulatory variants from whole-genome (WGS) and RNA sequencing (RNA-seq) data include cis-X (<xref rid="btac831-B7" ref-type="bibr">Liu <italic toggle="yes">et al.</italic>, 2020</xref>). It relies on allele specific as well as outlier high expression (OHE) to identify genes activated in cis, and subsequently associates them with potential driver mutation candidates. In contrast, CESAM (<xref rid="btac831-B16" ref-type="bibr">Weischenfeldt <italic toggle="yes">et al.</italic>, 2017</xref>) uses linear regression of gene expression on somatic copy number alterations (CNAs), while <xref rid="btac831-B13" ref-type="bibr">Rheinbay <italic toggle="yes">et al.</italic> (2020)</xref> introduced the concepts of recurrent SV breakpoints and SV juxtaposition.</p>
    <p>We provide an R package for the visualization and analysis of regulatory variants in cancer genome cohorts. Besides combining several features of the existing methods, we added consideration of gene-specific regulatory regions, sample aggregation and comprehensive result evaluation features, that no existing solution provides yet to the best of our knowledge. Subsequent analysis of a well-described, published cohort of medulloblastoma genomes demonstrates that Revana (REgulatory Variant ANAlysis) can effectively detect and illustrate known regulatory variants.</p>
  </sec>
  <sec>
    <title>2 Implementation</title>
    <sec>
      <title>2.1 Data input and preparation</title>
      <p>Revana requires processed data from deep WGS and RNA-seq for a cohort of tumor samples as input. Tab-separated value files providing SNP markers, copy numbers, structural variants, somatic SNVs and InDels and gene expression feature counts are used as input (hg19 or hg38) and need to be created prior to the application of Revana with any of the many available tools (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Material</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Identification of cis-activated genes</title>
      <p>Revana adopts the approach used by Liu <italic toggle="yes">et al.</italic>, combining allele-specific expression (ASE) and OHE to identify cis-activated genes that are potentially subject to variant-based upregulation. ASE statistics calculated from heterozygous SNP marker allele frequencies are compared to a balanced expression model established by Liu <italic toggle="yes">et al.</italic> OHE is determined using a leave-one-out test against a pre-filtered set of other tumor samples of the cohort and eliminates the need for a precalculated gene expression reference matrix.</p>
    </sec>
    <sec>
      <title>2.3 Associating genes with non-coding, regulatory variants</title>
      <p>To identify potential regulatory somatic variants responsible for the upregulation of cis-activated genes, Revana matches genes and variants using three alternative approaches. As also utilized in cis-X, it first considers variants of the same topologically associating domain (TAD) in which the gene is located. Cis-X prioritized SVs and CNAs and only considered somatic SNVs/InDels if no other variant type could be detected. Yet, since point mutations are frequent events in cancer genomes, their presence alone cannot determine genuine regulatory variant candidates. We found, that a more rigorous selection of SNVs by transcription factor binding site analysis with FIMO (<xref rid="btac831-B2" ref-type="bibr">Grant <italic toggle="yes">et al.</italic>, 2011</xref>) as used in cis-X, was not able to improve the predictive power with respect to cis-activation. Thus, we provide it only as a descriptive feature.</p>
      <p>Conversely, Revana associates genes irrespective of their cis-activation status with all types of variants from the same TAD. Thus, the strength of association for each mutation type with gene cis-activation can be estimated and compared (e.g. odds ratio, OR<sub>SNV/InDel</sub> = X, ORSV = Y).</p>
      <p>A second, complementary approach exploits gene-specific regulatory regions, so-called GeneHancers (<xref rid="btac831-B1" ref-type="bibr">Fishilevich <italic toggle="yes">et al.</italic>, 2017</xref>). Promoter and enhancer elements of each gene under investigation allow for the matching of mutations beyond the TAD as well as a more selective choice of point mutations within the same TAD. Optionally, ChiP-seq data, ideally tissue-matched, can provide regulatory regions specific to the samples under investigation and is then used for gene-to-variant association, result annotation and visualization.</p>
    </sec>
    <sec>
      <title>2.4 Automatic report generation and data visualization</title>
      <p>Subsequently, Revana creates a comprehensive HTML report that helps evaluate, prioritize and visualize candidate events and allows to compare results of different tumor subgroups.</p>
      <p>JavaScript-powered interactive illustrations show recurrently cis-activated genes across the cohort, highlight samples with different types of potential regulatory variants and provide multiple sorting and filtering options. This allows to prioritize between the discovered gene candidates and quickly elucidate genes repeatedly affected by comparable regulatory mechanisms. Moreover, recurrent SV juxtapositions can provide further support for systematically involved genetic mechanisms.</p>
      <p>For each discovered gene candidate, a separate document shows the recurrence of mutations, the expression and allelic imbalance of the gene across the investigated samples and tumor subgroups as well as more explicit statistics. A gene locus plot illustrates all present somatic variants and thus helps interpreting the detected somatic genomic events.</p>
      <p>Finally, the integrative genome viewer (IGV) plugin (<xref rid="btac831-B14" ref-type="bibr">Robinson <italic toggle="yes">et al.</italic>, 2022</xref>), facilitates interactive inspection of the gene TAD, other distant breakpoints and any available alignment directly within the browser.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Results</title>
    <p>To demonstrate Revana’s capabilities, we applied it to our cohort of 128 medulloblastomas from the International Cancer Genome Consortium (ICGC PedBrain) and identified a total of 3952 cis-activated candidate genes across the cohort, of which 1502 carry potential regulatory variants. Revana’s filtering and sorting features quickly revealed the known top candidates (<xref rid="btac831-F1" ref-type="fig">Fig. 1A</xref>). These include the two well-studied enhancer hijacking loci <italic toggle="yes">PRDM6</italic> (<xref rid="btac831-F1" ref-type="fig">Fig. 1B and C</xref>) (6/7 cases recognized; one case lacked sufficient SNP markers for ASE detection) (<xref rid="btac831-B9" ref-type="bibr">Northcott <italic toggle="yes">et al.</italic>, 2017</xref>) and <italic toggle="yes">GFI1B</italic> (4/4 cases) (<xref rid="btac831-B10" ref-type="bibr">Northcott <italic toggle="yes">et al.</italic>, 2014</xref>) as well as characteristic <italic toggle="yes">PVT1</italic> fusions (<xref rid="btac831-B11" ref-type="bibr">Northcott <italic toggle="yes">et al.</italic>, 2012</xref>). Gene locus illustrations summarize these genomic events (<xref rid="btac831-F1" ref-type="fig">Fig. 1C</xref>). Our results conclusively demonstrate that Revana can identify known and novel non-coding regulatory variants in cohorts of cancer genomes.</p>
    <fig position="float" id="btac831-F1">
      <label>Fig. 1.</label>
      <caption>
        <p>Workflow of Revana: (<bold>A</bold>) Cis-activated samples by gene: solid—cis-activated with GeneHancer-matched variant, transparent—cis-activated without GeneHancer-matched variant; (<bold>B</bold>) <italic toggle="yes">PRDM6</italic> expression across medulloblastoma subgroups; (<bold>C</bold>) <italic toggle="yes">PRDM6</italic> gene locus plot—recurrent <italic toggle="yes">SNCAIP</italic> tandem duplications cause upregulation</p>
      </caption>
      <graphic xlink:href="btac831f1" position="float"/>
    </fig>
    <p><italic toggle="yes">Financial Support</italic>: none declared.</p>
    <p><italic toggle="yes">Conflict of Interest</italic>: none declared.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btac831_Supplementary_Materials</label>
      <media xlink:href="btac831_supplementary_materials.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>We acknowledge the DKFZ's ODCF and GPCF core facilities for supporting the genomic sequencing and data processing. We thank Dr Martin Sill for his contributions on R code optimization.</p>
  </ack>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The data underlying this article is available in the GitHub repositories at <ext-link xlink:href="https://github.com/KiTZ-Heidelberg/revana-demo-data" ext-link-type="uri">https://github.com/KiTZ-Heidelberg/revana-demo-data</ext-link> and <ext-link xlink:href="https://github.com/KiTZ-Heidelberg/revana-demo-report" ext-link-type="uri">https://github.com/KiTZ-Heidelberg/revana-demo-report</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btac831-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fishilevich</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>GeneHancer: genome-wide integration of enhancers and target genes in GeneCards</article-title>. <source>Database</source>, <volume>2017</volume>, <fpage>1</fpage>–<lpage>17</lpage>.</mixed-citation>
    </ref>
    <ref id="btac831-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grant</surname><given-names>C.E.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>FIMO: scanning for occurrences of a given motif</article-title>. <source>Bioinformatics</source>, <volume>27</volume>, <fpage>1017</fpage>–<lpage>1018</lpage>.<pub-id pub-id-type="pmid">21330290</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haller</surname><given-names>F.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands</article-title>. <source>Nat. Commun</source>., <volume>10</volume>, <fpage>1</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">30602773</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Helmsauer</surname><given-names>K.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma</article-title>. <source>Nat. Commun</source>., <volume>11</volume>, <fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">31911652</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Horn</surname><given-names>S.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) <article-title>TERT promoter mutations in familial and sporadic melanoma</article-title>. <source>Science</source>, <volume>339</volume>, <fpage>959</fpage>–<lpage>961</lpage>.<pub-id pub-id-type="pmid">23348503</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname><given-names>F.W.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) <article-title>Highly recurrent TERT promoter mutations in human melanoma</article-title>. <source>Science</source>, <volume>339</volume>, <fpage>957</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">23348506</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Discovery of regulatory noncoding variants in individual cancer genomes by using cis-X</article-title>. <source>Nat. Genet</source>. <volume>52</volume>, <fpage>811</fpage>–<lpage>818</lpage>.<pub-id pub-id-type="pmid">32632335</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Montefiori</surname><given-names>L.E.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia</article-title>. <source>Cancer Discov</source>., <volume>11</volume>, <fpage>2846</fpage>–<lpage>2867</lpage>.<pub-id pub-id-type="pmid">34103329</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Northcott</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2012</year>) <article-title>Subgroup-specific structural variation across 1,000 medulloblastoma genomes</article-title>. <source>Nature</source>, <volume>488</volume>, <fpage>49</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">22832581</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Northcott</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma</article-title>. <source>Nature</source>, <volume>511</volume>, <fpage>428</fpage>–<lpage>434</lpage>.<pub-id pub-id-type="pmid">25043047</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Northcott</surname><given-names>P.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>The whole-genome landscape of medulloblastoma subtypes</article-title>. <source>Nature</source>, <volume>547</volume>, <fpage>311</fpage>–<lpage>317</lpage>.<pub-id pub-id-type="pmid">28726821</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Remke</surname><given-names>M.</given-names></string-name></person-group> (<year>2013</year>) <article-title>TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma</article-title>. <source>Acta Neuropathol</source>., <volume>126</volume>, <fpage>917</fpage>–<lpage>929</lpage>.<pub-id pub-id-type="pmid">24174164</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rheinbay</surname><given-names>E.</given-names></string-name></person-group><etal>et al</etal>; <collab>PCAWG Consortium</collab>. (<year>2020</year>) <article-title>Analyses of non-coding somatic drivers in 2,658 cancer whole genomes</article-title>. <source>Nature</source>, <volume>578</volume>, <fpage>102</fpage>–<lpage>111</lpage>.<pub-id pub-id-type="pmid">32025015</pub-id></mixed-citation>
    </ref>
    <ref id="btac831-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robinson</surname><given-names>J.T.</given-names></string-name></person-group><etal>et al</etal> (<year>2022</year>) <article-title>igv.js: an embeddable JavaScript implementation of the Integrative Genomics Viewer (IGV)</article-title>. <source>Bioinformatics</source>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btac830</pub-id>.</mixed-citation>
    </ref>
    <ref id="btac831-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vinagre</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2013</year>) <article-title>Frequency of TERT promoter mutations in human cancers</article-title>. <source>Nat. Commun</source>., <volume>4</volume>, <fpage>1</fpage>–<lpage>6</lpage>.</mixed-citation>
    </ref>
    <ref id="btac831-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weischenfeldt</surname><given-names>J.</given-names></string-name></person-group><etal>et al</etal> (<year>2017</year>) <article-title>Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking</article-title>. <source>Nat. Genet</source>., <volume>49</volume>, <fpage>65</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">27869826</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
